These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6395527)

  • 21. [Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine].
    Saletu B; Grünberger J; Anderer P; Chwatal K
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():45-55. PubMed ID: 1683340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaco-EEG and psychometric studies with a novel selective benzodiazepine agonist/antagonist Ro 23-0364.
    Saletu B; Grünberger J; Cepko H
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):421-37. PubMed ID: 2888736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):362-73. PubMed ID: 3525428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
    Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
    Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
    Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
    Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
    Nobuhara K
    Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
    Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM
    Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.
    Saletu-Zyhlarz GM; Anderer P; Wolzt M; Semlitsch HV; Assandri A; Nessi P; Nannipieri F; Rosini S; Saletu B
    Neuropsychobiology; 2009; 59(2):100-9. PubMed ID: 19365150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment.
    Semlitsch HV; Anderer P; Saletu B; Hochmayer I
    Neuropsychobiology; 1990-1991; 24(1):49-56. PubMed ID: 2132641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
    Saletu B; Grünberger J; Linzmayer L
    Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.
    Saletu B; Grünberger J; Volavka J; Berner P
    Arzneimittelforschung; 1979; 29(4):700-4. PubMed ID: 582772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analytic study on EEG features of aging with/without psychiatric disorders: focussing at the alterations in the EEGs of the healthy, depressive and demented elderlies].
    Saito N
    Seishin Shinkeigaku Zasshi; 1995; 97(10):801-24. PubMed ID: 8552725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of pharmacodynamic properties of psychotropic drugs: quanitative EEG, psychometric and blood level investigations in normals and patients.
    Saletu B; Grünberger J
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):45-58. PubMed ID: 419165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency].
    Kopp H
    Fortschr Med; 1979 Feb; 97(7):307-12. PubMed ID: 437665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Demonstration of bencyclane effects in a clinico-pharmacologic vigilance model].
    Herrmann WM; Kern U
    Z Gerontol; 1984; 17(5):261-70. PubMed ID: 6395526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CNS pharmacology and clinical therapeutic effects of oxiracetam.
    Itil TM; Menon GN; Songar A; Itil KZ
    Clin Neuropharmacol; 1986; 9 Suppl 3():S70-2. PubMed ID: 3594458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classification and determination of cerebral biovailability of psychotropic drugs by quantitative "pharmaco-EEG" and psychometric investigations (studies with AX-A411-BS).
    Saletu B; Grünberger J; Linzmayer L
    Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):449-59. PubMed ID: 21853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification and assessment of cerebral bioavailability of lopirazepam (D-12524) by quantitative EEG and psychometric analysis.
    Saletu B; Grünberger J; Linzmayer L; Stadler R
    Arzneimittelforschung; 1980; 30(3):513-8. PubMed ID: 6104496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.